Castle Biosciences, Inc. (CSTL) key performance indicators and operating metrics (12 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Adjusted Gross Margin | 76.00 percent | FY2026-Q1 |
| Gross Margin (GAAP) | 73.00 percent | FY2026-Q1 |
| DecisionDx Melanoma Test Reports Delivered | 10.02K | FY2026-Q1 |
| DecisionDx Squamous Cell Carcinoma Test Reports Delivered | 3.7K | FY2026-Q1 |
| DecisionDx Uveal Melanoma Test Reports Delivered | 492.00 | FY2026-Q1 |
| TissueCypher Barrett's Esophagus Test Reports Delivered | 11.75K | FY2026-Q1 |
| MyPath Melanoma Test Reports Delivered | 973.00 | FY2026-Q1 |
| Non-Dermatologic Test Revenue | 42.6M | FY2026-Q1 |
| Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization | 11.5M | FY2025-Q4 |
| Total Test Reports Delivered | 26.84K | FY2025-Q3 |
| Adjusted Revenue | 86.2M | FY2025-Q2 |
| IDgenetix Test Reports Delivered | 1.03K | FY2025-Q2 |
Back to CSTL overview · CSTL earnings · CSTL holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.